×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RVMD – revolution medicines, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RVMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/24
06:03 pm
rvmd
Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. [CBS News]
Low
Report
Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. [CBS News]
4/22
10:30 am
rvmd
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $147.00 to $171.00. They now have an "outperform" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $147.00 to $171.00. They now have an "outperform" rating on the stock.
4/22
08:07 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $169.00 price target on the stock.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $169.00 price target on the stock.
4/21
05:35 pm
rvmd
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Medium
Report
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
4/21
05:30 pm
rvmd
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Medium
Report
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
4/21
11:23 am
rvmd
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Low
Report
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
4/20
10:58 am
rvmd
AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
Low
Report
AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
4/20
09:24 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
04:02 pm
rvmd
revolution medicines, inc.
MISS
Report
-1.1%
revolution medicines, inc.
11/5/2025
04:02 pm
rvmd
revolution medicines, inc.
MISS
Report
3.4%
revolution medicines, inc.
8/6/2025
04:02 pm
rvmd
revolution medicines, inc.
MISS
Report
-4.7%
revolution medicines, inc.
5/7/2025
04:02 pm
rvmd
revolution medicines, inc.
MISS
Report
11.3%
revolution medicines, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
07:26 pm
rvmd
Form 4 Revolution Medicines, For: Apr 15 Filed by: GOLDSMITH MARK A
Low
Report
Form 4 Revolution Medicines, For: Apr 15 Filed by: GOLDSMITH MARK A
4/17
05:17 pm
rvmd
Form 8-K Revolution Medicines, For: Apr 14
Low
Report
Form 8-K Revolution Medicines, For: Apr 14
4/16
05:07 pm
rvmd
Form 8-K Revolution Medicines, For: Apr 14
Low
Report
Form 8-K Revolution Medicines, For: Apr 14
4/15
05:26 pm
rvmd
Form 424B5 Revolution Medicines,
Low
Report
Form 424B5 Revolution Medicines,
4/15
05:25 pm
rvmd
Form 424B5 Revolution Medicines,
Low
Report
Form 424B5 Revolution Medicines,
4/15
04:54 pm
rvmd
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
Low
Report
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
4/15
04:02 pm
rvmd
Form 305B2 Revolution Medicines,
Low
Report
Form 305B2 Revolution Medicines,
4/15
06:12 am
rvmd
Form FWP Revolution Medicines, Filed by: Revolution Medicines, Inc.
Medium
Report
Form FWP Revolution Medicines, Filed by: Revolution Medicines, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
8.7%
3/18 Form SEC STAFF LETTER Revolution Medicines, 7.6%
4/16 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 6.6%
2/24 Form SC 13G Revolution Medicines, Filed by: Cormorant Asset Management, LP 4.5%
2/14 Form 4 Revolution Medicines, For: Feb 12 Filed by: Kelsey Stephen Michael 3.8%
2/18 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.3%
3/20 Form 8-K Revolution Medicines, For: Mar 18 3.1%
4/21 Form 8-K Revolution Medicines, For: Apr 17 2.6%
2/12 Form 3 Revolution Medicines, For: Feb 12 Filed by: GOEDDEL DAVID V 2.4%
4/17 Bill.com Holdings (NASDAQ: RVMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.7%
3/18 Form SEC STAFF LETTER Revolution Medicines, 7.6%
4/16 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 6.6%
2/24 Form SC 13G Revolution Medicines, Filed by: Cormorant Asset Management, LP 4.5%
2/14 Form 4 Revolution Medicines, For: Feb 12 Filed by: Kelsey Stephen Michael 3.8%
2/18 Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.3%
3/20 Form 8-K Revolution Medicines, For: Mar 18 3.1%
4/21 Form 8-K Revolution Medicines, For: Apr 17 2.6%
2/12 Form 3 Revolution Medicines, For: Feb 12 Filed by: GOEDDEL DAVID V 2.4%
4/17 Bill.com Holdings (NASDAQ: RVMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.7%
TOP News Decliners
3/12
Form SEC STAFF LETTER Revolution Medicines,
-17.9%
5/1 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -5.7%
2/20 Form 4 Revolution Medicines, For: Feb 18 Filed by: Exter Neil -3.9%
2/14 Form SC 13G/A Revolution Medicines, Filed by: Boxer Capital, LLC -2.3%
3/30 Form 10-K Revolution Medicines, For: Dec 31 -1.9%
3/18 Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program -1.6%
2/19 Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs [Yahoo! Finance News] -0.9%
3/9 New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute -0.4%
2/13 Form SC 13G Revolution Medicines, Filed by: Boxer Capital, LLC -0.3%
5/1 Bill.com Holdings (NASDAQ: RVMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock. -5.7%
2/20 Form 4 Revolution Medicines, For: Feb 18 Filed by: Exter Neil -3.9%
2/14 Form SC 13G/A Revolution Medicines, Filed by: Boxer Capital, LLC -2.3%
3/30 Form 10-K Revolution Medicines, For: Dec 31 -1.9%
3/18 Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program -1.6%
2/19 Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs [Yahoo! Finance News] -0.9%
3/9 New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute -0.4%
2/13 Form SC 13G Revolution Medicines, Filed by: Boxer Capital, LLC -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: